This case highlights the role of TPR::NTRK1 fusion in driving abnormal melanocyte proliferation and the potential contribution of MCL1 amplification to tumor progression. These findings provide insights into the genetic underpinnings of APN in CMN and suggest potential therapeutic targets for high-risk lesions.

2 days ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • MCL1 (Myeloid cell leukemia 1) • PRAME (Preferentially Expressed Antigen In Melanoma) • MLANA (Melan-A) • NTRK (Neurotrophic receptor tyrosine kinase) • CD99 (CD99 Molecule)

NTRK fusion

Larotrectinib in patients with tropomyosin receptor kinase fusion solid tumors in Spain (SPAINTRK). (PubMed, Eur J Cancer)

Larotrectinib evoked broad and durable antitumor activity in a plethora of solid tumors with NTRK fusions. Safety profile was consistent with that of clinical trials, even after long-term administration. While NGS use is increasing, broader access is needed.

2 days ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK3 (Neurotrophic tyrosine kinase, receptor, type 3) • NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK fusion

Vitrakvi (larotrectinib)

TH-CAR-027 for Grade 4 Gliomas (clinicaltrials.gov)

P1, N=21, Not yet recruiting, Shanghai Tongji Hospital, Tongji University School of Medicine

3 days ago

New P1 trial

BRAF (B-raf proto-oncogene) • CD276 (CD276 Molecule) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • BRAF V600 • NTRK fusion

An Open-Label, Single-Center, Multi-Cohort, Phase II Study Evaluating the Safety and Efficacy of Vebreltinib-Based Combination Therapy in Previously Treated Patients with Locally Advanced or Metastatic MET-Overexpressing Non-Small Cell Lung Cancer (ChiCTR2500112942)

P2, N=52, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

6 days ago

New P2 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF V600E • KRAS mutation • EGFR mutation • BRAF V600 • ALK rearrangement • MET exon 14 mutation • MET overexpression • ALK fusion • RET mutation • ROS1 fusion • ROS1 rearrangement • MET mutation • MET expression • RET rearrangement • NTRK fusion

docetaxel • Jiataile (sacituzumab tirumotecan) • bozitinib (APL-101)

A First-In-Human, Multicenter, Open-Label Phase I/II Investigational Study to Evaluate the Safety, Tolerability, Pharmacokinetics, And Preliminary Efficacy of KY-0301 as monotherapy or combined with other anticancer agents in Patients with advanced Solid Tumors (ChiCTR2600116103)

P1/2, N=120, Recruiting, Shanghai East Hospital; Novatim Immune Therapeutics (Zhejiang) Co., Ltd.

6 days ago

New P1/2 trial

HER-2 (Human epidermal growth factor receptor 2) • PD-L1 (Programmed death ligand 1) • KRAS (KRAS proto-oncogene GTPase) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • MSI (Microsatellite instability) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

PD-L1 expression • KRAS mutation • EGFR mutation • MSI-H/dMMR • BRAF mutation • EGFR L858R • EGFR exon 19 deletion • EGFR T790M • ALK rearrangement • EGFR wild-type • MET exon 14 mutation • KRAS wild-type • RAS wild-type • ROS1 fusion • ROS1 rearrangement • MET mutation • NTRK fusion

Phase I Clinical Study Evaluating the Safety, Tolerability, Pharmacokinetic Profile, and Preliminary Efficacy of BL-B01D1 for Injection in Patients with Locally Advanced or Metastatic Solid Tumors (ChiCTR2500113663)

P1, N=500, Not yet recruiting, Sun Yat-sen University Cancer Center; Sichuan Baili Pharmaceutical Co., Ltd.

6 days ago

New P1 trial

BRAF V600E • KRAS mutation • EGFR mutation • KRAS G12C • BRAF V600 • RET fusion • MET exon 14 mutation • ALK fusion • EGFR L861Q • RET mutation • ROS1 fusion • EGFR G719X • MET mutation • EGFR S768I • KRAS G12 • NTRK fusion

izalontamab brengitecan (BL-B01D1)

Glumetinib combined with platinum-based chemotherapy for the treatment of MET-overexpressing locally advanced or metastatic non-small cell lung cancer: A single-arm, multicenter study (ChiCTR2600117342)

P1, N=48, Not yet recruiting, West China Hospital of Sichuan University; West China Hospital of Sichuan University

6 days ago

New P1 trial

EGFR (Epidermal growth factor receptor) • HER-2 (Human epidermal growth factor receptor 2) • BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • MET (MET proto-oncogene, receptor tyrosine kinase) • RET (Ret Proto-Oncogene) • ROS1 (Proto-Oncogene Tyrosine-Protein Kinase ROS) • NTRK (Neurotrophic receptor tyrosine kinase)

EGFR mutation • BRAF mutation • BRAF V600 • HER-2 mutation • RET fusion • MET overexpression • HER-2 exon 20 insertion • ALK fusion • RET mutation • ROS1 fusion • MET mutation • NTRK fusion

carboplatin • pemetrexed • Haiyitan (gumarontinib)

A CLIP on the Ear: Spitz Melanocytoma Harbouring a CLIP2-BRAF Gene Fusion. (PubMed, Case Rep Dermatol Med)

Here, we present the case of a spitzoid melanocytoma harbouring a rare BRAF gene fusion. A brief overview of the literature is also touched upon.

8 days ago

Journal

BRAF (B-raf proto-oncogene) • ALK (Anaplastic lymphoma kinase) • NTRK (Neurotrophic receptor tyrosine kinase)

BRAF mutation • ALK mutation • ROS1 fusion • NTRK fusion

10d

NTRK-rearranged soft tissue sarcoma that originated from the head and neck with a robust response to the TRK inhibitor larotrectinib. (PubMed, Int Cancer Conf J)

Concurrent comprehensive genome profiling (FoundationOne® CDx) confirmed the LMNA-NTRK1 fusion, and treatment with the TRK inhibitor larotrectinib was started. With larotrectinib treatment, the tumor shrank in size at an early stage, and the response has been maintained for > 2 years.

10 days ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • LMNA (Lamin A/C) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK positive • NTRK fusion

FoundationOne® CDx

Vitrakvi (larotrectinib)

15d

Larotrectinib in Adjuvant and First-Line Treatment for Metastatic NTRK Fusion Colon Cancer. (PubMed, Asia Pac J Clin Oncol)

At the time of this clinical case report, therapy is ongoing for 21 months without any signs of further disease progression. This study demonstrates the efficacy and safety of larotractinib as both adjuvant therapy and first-line therapy in a complex clinical case of colon cancer against the background of severe concomitant pathology, when chemotherapy is contraindicated.

15 days ago

Journal

NTRK1 (Neurotrophic tyrosine kinase, receptor, type 1) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK fusion

Vitrakvi (larotrectinib)

15d

Neurotrophin NGF/TrkA and BDNF/TrkB signaling orchestrates the immune microenvironment in osteosarcoma. (PubMed, Front Immunol)

Clinical and preclinical signals collectively support testing neurotrophin-targeted strategies to recalibrate myeloid composition, enhance antigen presentation, and restore T-cell access to tumor beds. The purpose of this review is to synthesize current evidence and propose a translational roadmap for targeting NGF/TrkA and BDNF/TrkB to remodel antitumor immunity in osteosarcoma.

15 days ago

Review • Journal • IO biomarker

NTRK2 (Neurotrophic tyrosine kinase, receptor, type 2) • MMP2 (Matrix metallopeptidase 2) • NTRK (Neurotrophic receptor tyrosine kinase)

NTRK positive • NTRK fusion